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Figure 1. Immune proﬁles of healthy controls and GVHD patients.
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CGVHD develops in more than 50% of survivors of allogeneic
stem cell transplantation and is responsible for mortality in
one third of patients. Long-term immunosuppressive ther-
apy with steroids is the standard treatment. ECP is successful
in about 50% of the patients after 3e 6 months of therapy. To
deﬁnemarkers that might predict successful ECP therapy, we
performed an immunological assessment of 22 patients with
cGVHD prior to initiating ECP. In addition, a comprehensive
assessment of organ system involvement using NIH
Consensus response assessment tools was done at study
entry and at six months. Eighteen patients completed the
study with improvement of GvHD symptoms observed in
eleven patients; seven patients failed to respond to therapy.
PBMCs from leukopheresed blood were obtained prior to the
onset of ECP therapy. Patients who responded to ECP therapy
consistently had a lower CD4/CD8 ratio than non-responders
(0.80  0.64 vs. 3.7  3.1, p < 0.01). The percentages of CD4+
and CD8+ T cells that expressed CD25, CD45RA, or FoxP3
were not different between the two groups. Within the B cell
populations, the phenotype of CD21-CD24+ cells varied be-
tween responders and non-responders with fewer cells
expressing IgD in the responders than in the non-re-
sponders; 61%  19% of CD21-CD24+ B cells were IgD+CD27-
in patient who responded to ECP, as compared to 80%  10%
in patients who did not respond to ECP, p< 0.05. The identity
of these cells is not known, but they may represent a mem-
ory B cell compartment. In addition to obtaining PBMCs prior
to ECP, cells were also obtained at 2, 4, and 6months after theonset of ECP to deﬁne parameters that might track the re-
covery of GvHD. The percentage of CD3-CD20- cells that were
CD34+ cells increased in patients responding to ECP, but
decreased in patients not responding to ECP. The results of
our pilot study suggested that the lymphocyte phenotype
might be a useful predictive marker for successful ECP
therapy. In addition, changes in the CD34+ population might
provide an objective marker for ECP responsiveness.411
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Background: Proteinuria after allogeneic hematopoietic cell
transplantation (allo-HCT) can be multifactorial. Renal
dysfunction and ESRD are more frequent after allo-HCT but
the reports of chronic graft versus host disease affecting the
kidney are rare.
Methods: We report the clinical and natural history of 7
patients presenting with nephrotic range proteinuria (NRP)
deﬁned as >¼3g/24hrs after allo-HCT.
Results:Median age at transplant was 50 years (range 42-58)
years. Four of seven patients had well matched unrelated
donor and three had fully matched sibling grafts (all blood
stem cells, PBSC). The development of NRP was a late event
occurring at a median of +682 d of allo-HSCT (range 342-
880days). All but one of seven patients had evidence of other
chronic GVHD at the time of diagnosis of NRP. Median serum
creatinine at diagnosis was 1.17mg/dl.
Renal biopsy was performed in all cases. Histologic pat-
terns were variable with membranous glomerulonephritis
(n¼4); minimal change disease (n¼1), focal segmental glo-
merulosclerosis (n¼1) and tubulitis (n¼1) observed. At the
onset of NRP 3 out of 7 patients were off all immunosup-
pressants and four were still on tapering doses of immuno-
suppression. Indication for allo-HCT was AML (n¼3), CLL
(n¼2), Multiple myeloma (n¼1) and MDS (n¼1) and in all
cases in remission at the time NRP diagnosis.
